Trial Profile
Phase II Trial of In Situ Tumor Vaccination Using Durvalumab and "Booster" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Mar 2023 Status changed from active, no longer recruiting to discontinued.
- 12 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2026.